Skip Navigation



Rheumatology Advance Access published online on November 22, 2006

Rheumatology, doi:10.1093/rheumatology/kel382
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
46/4/678    most recent
kel382v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sut, N.
Right arrow Articles by Yazici, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sut, N.
Right arrow Articles by Yazici, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

A cost analysis of Behçet's syndrome in Turkey

N. Sut, E. Seyahi1, S. Yurdakul1, M. Senocak and H. Yazici1

Department of Biostatistics, Cerrahpasa Medical Faculty, University of Istanbul and 1Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.

Correspondence to: Correspondence to: Sebahattin Yurdakul, MD, Atakoy 9, Kisim, D 12, B Kapisi, Daire: 12, 34156 Istanbul, Turkey. E-mail: profsyurdakul{at}yahoo.com


   Abstract

Objective. Behçet's syndrome (BS), a common chronic inflammatory disease in Turkey, results in considerable morbidity and increased mortality. We aimed to estimate its direct and indirect costs.

Methods. We studied 119 (78 male/41 female) patients with BS at our multidisciplinary BS out-patient clinic in Istanbul, between March and July 2005. The mean age and disease duration were 35 ± 9 and 10 ± 6 S.D. yrs. According to the primary clinical problem, patients were divided into: (i) ocular; (ii) vascular; (iii) neurological and (iv) mucocutaneous-joint disease subgroups. They were interviewed with a standardized questionnaire addressing: (a) direct costs such as medication, diagnostic tests, hospital visits, hospitalization fees and lodging and transportation expenses and (b) indirect costs such as lost workdays and wages. The costs were assessed retrospectively by assessing the expenses within a year of the survey and were expressed as US$ mean ± S.D.

Results. The mean annual total cost per patient was US$ 3226 ± 3488 (S.D.). The direct cost accounted for 68% of the total cost. Medication expenses made up 79% of the total direct cost. About 42% of the patients reported lost workdays that averaged 119 ± 96 days S.D. Among the clinical subgroups mucocutaneous-joint involvement (US$ 1180 ± 1053) had the lowest economic impact while the neurological disease (US$ 5005 ± 2707) had the highest.

Conclusion. In this first cost of illness study in BS, the neurological involvement had the highest annual cost. Direct costs were higher than the indirect costs. Drug costs were the major cost driver. BS causes considerable economic burden for the health care system in Turkey.

KEY WORDS: Cost of illness, Behçet's syndrome, Direct costs, Indirect costs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.